Space-Air-Ground Integrated 6G Wireless Communication Networks: A Review of Antenna Technologies and Application Scenarios

A review of technological solutions and advances in the framework of a Vertical Heterogeneous Network (VHetNet) integrating satellite, airborne and terrestrial networks is presented. The disruptive features and challenges offered by a fruitful cooperation among these segments within a ubiquitous and seamless wireless connectivity are described. The available technologies and the key research directions for achieving global wireless coverage by considering all these layers are thoroughly discussed. Emphasis is placed on the available antenna systems in satellite, airborne and ground layers by highlighting strengths and weakness and by providing some interesting trends in research. A summary of the most suitable applicative scenarios for future 6G wireless communications are finally illustrated

A Distributed IoT Air Quality Measurement System for High-Risk Workplace Safety Enhancement

The safety of an operator working in a hazardous environment is a recurring topic in the technical literature of recent years, especially for high-risk environments such as oil and gas plants, refineries, gas depots, or chemical industries. One of the highest risk factors is constituted by the presence of gaseous substances such as toxic compounds such as carbon monoxide and nitric oxides, particulate matter or indoors, in closed spaces, low oxygen concentration atmospheres, and high concentrations of CO2 that can represent a risk for human health. In this context, there exist many monitoring systems for lots of specific applications where gas detection is required. In this paper, the authors present a distributed sensing system based on commercial sensors aimed at monitoring the presence of toxic compounds generated by a melting furnace with the aim of reliably detecting the insurgence of dangerous conditions for workers. The system is composed of two different sensor nodes and a gas analyzer, and it exploits commercial low-cost commercially available sensors

Sampling protein motion and solvent effect during ligand binding.

An exhaustive description of the molecular recognition mechanism between a ligand and its biological target is of great value because it provides the opportunity for an exogenous control of the related process. Very often this aim can be pursued using high resolution structures of the complex in combination with inexpensive computational protocols such as docking algorithms. Unfortunately, in many other cases a number of factors, like protein flexibility or solvent effects, increase the degree of complexity of ligand/protein interaction and these standard techniques are no longer sufficient to describe the binding event. We have experienced and tested these limits in the present study in which we have developed and revealed the mechanism of binding of a new series of potent inhibitors of Adenosine Deaminase. We have first performed a large number of docking calculations, which unfortunately failed to yield reliable results due to the dynamical character of the enzyme and the complex role of the solvent. Thus, we have stepped up the computational strategy using a protocol based on metadynamics. Our approach has allowed dealing with protein motion and solvation during ligand binding and finally identifying the lowest energy binding modes of the most potent compound of the series, 4-decyl-pyrazolo[1,5-a]pyrimidin-7-one

Population-Based Study of New Mutations Causing Sandhoff Disease in Argentina

2pSandhoff Disease (SD) is a lysosomal storage disorder caused by mutations in the HEXB gene. A high incidence of SD has been described in an Argentine region called ‘‘Valle de Traslasierra.’’ Mutations c.445þ1G>A and p.S261Cfs12X were found in 98.7% and 1.3% of mutant alleles, respectively. In previous population-based studies, the carrier frequency has been estimated to be 1 in 16 to 29, all heterozygous with c.445þ1G>A. Recently, we detected new mutations in 5 Argentinian patients: c.1082þ5G>A, c.1242þ1G>A, c.1451G>A (p.Gly484Glu), c.1597C>T (p.Arg533Cys) and c.1601G>A (p.Cys534Tyr).Fil: Mugnaini, Julia. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Centro de Estudio de las Metabolopatías Congénitas (CEMECO). Hospital de Niños. Cátedra de Clínica Pediátrica; Argentina.Fil: Dardis, Andrea. Hospital Universitario ‘‘Santa Maria del la Misericordia’’. Centro Coordinador Regional de Enfermedades Raras, Udine; Italia.Fil: Dodelson de Kremer, Raquel. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Hospital de Niños. Centro de Estudio de las Metabolopatías Congénitas (CEMECO). Cátedra de Clínica Pediátrica; ArgentinaFil: Oller Ramírez, Ana María. Universidad Nacional de Córdoba. Facultad de Ciencias Medicas. Hospital de Niños. Centro de Estudio de las Metabolopatías Congénitas (CEMECO). Cátedra de Clínica Pediátrica; Argentina.Fil: Azar, Nydia Beatriz. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Centro de Estudio de las Metabolopatías Congénitas (CEMECO). Hospital de Niños. Cátedra de Clínica Pediátrica; ArgentinaFil: Becerra, Adriana. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Centro de Estudio de las Metabolopatías Congénitas (CEMECO). Hospital de Niños. Cátedra de Clínica Pediátrica; Argentina.Fil; Zampieri, S. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Centro de Estudio de las Metabolopatías Congénitas (CEMECO). Hospital de Niños. Cátedra de Clínica Pediátrica; Argentina.Fil: Guelbert, Norberto. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Centro de Estudio de las Metabolopatías Congénitas (CEMECO). Hospital de Niños. Cátedra de Clínica Pediátrica; Argentina.Bioquímica y Biología Molecula

Exploiting the Pyrazolo[3,4-d]pyrimidin-4-one ring system as a useful template to obtain potent adenosine deaminase inhibitors,

A number of pyrazolo[3,4-d]pyrimidin-4-ones bearing either alkyl or arylalkyl substituents in position 2 of the nucleus were synthesized and tested for their ability to inhibit adenosine deaminase (ADA) from bovine spleen. The 2-arylalkyl derivatives exhibited excellent inhibitory activity, showing Ki values in the nanomolar/ subnanomolar range. The most active compound, 1-(4-((4-oxo-4,5-dihydropyrazolo[3,4-d]pyrimidin-2- yl)methyl)phenyl)-3-(4-(trifluoromethyl)phenyl)urea, 14d, was tested in rats with colitis induced by 2,4- dinitrobenzenesulfonic acid to assess its efficacy to attenuate bowel inflammation. The treatment with 14d induced a significant amelioration of both systemic and intestinal inflammatory alterations in animals with experimental colitis. Docking simulations of the synthesized compounds into the ADA catalytic site were also performed to rationalize the structure-activity relationships observed and to highlight the key pharmacophoric elements of these products, thus prospectively guiding the design of novel ADA inhibitors

Exploiting the Pyrazolo[3,4-d]pyrimidin-4-one ring system as a useful template to obtain potent adenosine deaminase inhibitors,

A number of pyrazolo[3,4-d]pyrimidin-4-ones bearing either alkyl or arylalkyl substituents in position 2 of the nucleus were synthesized and tested for their ability to inhibit adenosine deaminase (ADA) from bovine spleen. The 2-arylalkyl derivatives exhibited excellent inhibitory activity, showing Ki values in the nanomolar/ subnanomolar range. The most active compound, 1-(4-((4-oxo-4,5-dihydropyrazolo[3,4-d]pyrimidin-2- yl)methyl)phenyl)-3-(4-(trifluoromethyl)phenyl)urea, 14d, was tested in rats with colitis induced by 2,4- dinitrobenzenesulfonic acid to assess its efficacy to attenuate bowel inflammation. The treatment with 14d induced a significant amelioration of both systemic and intestinal inflammatory alterations in animals with experimental colitis. Docking simulations of the synthesized compounds into the ADA catalytic site were also performed to rationalize the structure-activity relationships observed and to highlight the key pharmacophoric elements of these products, thus prospectively guiding the design of novel ADA inhibitors

Radical exchange reaction of multi-spin isoindoline nitroxides followed by EPR spectroscopy

The synthesis of a rigid, isoindoline-functionalized tetraphenylmethane multi-spin system is described. The isoindoline nitroxide groups are used in a nitroxide exchange reaction with a TEMPO containing alkoxyamine. Using EPR spectroscopy it is possible to follow the exchange process and thereby find the optimal experimental conditions to have the maximum yield. The presented approach could be used to study the nitroxide exchange process of various systems and to determine the kinetics of the exchange process. The presented molecular components can be used as tectons in the construction of covalently linked organic networks or as model systems for EPR distance measurements

The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice.

RATIONALE Using the drinking-in-the-dark (DID) model, we compared the effects of a novel mu-opioid receptor antagonist, GSK1521498, with naltrexone, a licensed treatment of alcohol dependence, on ethanol consumption in mice. OBJECTIVE We test the ability of GSK1521498 to reduce alcohol consumption and compare its intrinsic efficacy to that of naltrexone by comparing the two drugs at doses matched for equivalent receptor occupancy. METHODS Thirty-six C57BL/6J mice were tested in a DID procedure. In 2-day cycles, animals experienced one baseline, injection-free session, and one test session when they received two injections, one of test drug and one placebo. All animals received GSK1521498 (0, 0.1, 1 and 3 mg/kg, i.p., 30 min pre-treatment) and naltrexone (0, 0.1, 1 and 3 mg/kg, s.c. 10 min pre-treatment) in a cross-over design. Receptor occupancies following the same doses were determined ex vivo in separate groups by autoradiography, using [3H]DAMGO. Binding in the region of interest was measured integrally by computer-assisted microdensitometry and corrected for non-specific binding. RESULTS Both GSK1521498 and naltrexone dose-dependently decreased ethanol consumption. When drug doses were matched for 70-75 % receptor occupancy, GSK1521498 3 mg/kg, i.p., caused a 2.5-fold greater reduction in alcohol consumption than naltrexone 0.1 mg/kg, s.c. Both GSK1521498 and naltrexone significantly reduced sucrose consumption at a dose of 1 mg/kg but not 0.1 mg/kg. In a test of conditioned taste aversion, GSK1521498 (3 mg/kg) reduced sucrose consumption 24 h following exposure to a conditioning injection. CONCLUSIONS Both opioid receptor antagonists reduced alcohol consumption but GK1521498 has higher intrinsic efficacy than naltrexone